Artikel ; Online: Navigating the Uncertainties of COVID-19-Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis.
The Journal of infectious diseases
2021 Band 224, Heft 10, Seite(n) 1631–1640
Abstract: ... pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA). Compared to IAPA, the majority ... of influenza and COVID-19 may explain these discrepancies. Whether CAPA represents a distinct entity is still ... environmental/epidemiological factors. In this article, we discuss the similarities and differences between influenza-associated ...
| Abstract | Invasive pulmonary aspergillosis (IPA) is increasingly recognized as a life-threatening superinfection of severe respiratory viral infections, such as influenza. The pandemic of Coronavirus Disease 2019 (COVID-19) due to emerging SARS-CoV-2 rose concern about the eventuality of IPA complicating COVID-19 in intensive care unit patients. A variable incidence of such complication has been reported, which can be partly attributed to differences in diagnostic strategy and IPA definitions, and possibly local environmental/epidemiological factors. In this article, we discuss the similarities and differences between influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA). Compared to IAPA, the majority of CAPA cases have been classified as putative rather than proven/probable IPA. Distinct physiopathology of influenza and COVID-19 may explain these discrepancies. Whether CAPA represents a distinct entity is still debatable and many questions remain unanswered, such as its actual incidence, the predisposing role of corticosteroids or immunomodulatory drugs, and the indications for antifungal therapy. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Antifungal Agents/therapeutic use ; Aspergillosis/complications ; Aspergillosis/drug therapy ; COVID-19/complications ; Humans ; Influenza, Human/complications ; Influenza, Human/drug therapy ; Invasive Pulmonary Aspergillosis/complications ; Invasive Pulmonary Aspergillosis/diagnosis ; Invasive Pulmonary Aspergillosis/drug therapy ; Pulmonary Aspergillosis/complications ; Pulmonary Aspergillosis/drug therapy ; SARS-CoV-2 | ||||||||||
| Chemische Substanzen | Antifungal Agents | ||||||||||
| Sprache | Englisch | ||||||||||
| Erscheinungsdatum | 2021-03-29 | ||||||||||
| Erscheinungsland | United States | ||||||||||
| Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't | ||||||||||
| ZDB-ID | 3019-3 | ||||||||||
| ISSN | 1537-6613 ; 0022-1899 | ||||||||||
| ISSN (online) | 1537-6613 | ||||||||||
| ISSN | 0022-1899 | ||||||||||
| DOI | 10.1093/infdis/jiab163 | ||||||||||
| Signatur |
|
||||||||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Uh II Zs.50: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 445: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.